Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model by Nagy, Zoltán et al.
Am J Cancer Res 2015;5(12):3645-3658
www.ajcr.us /ISSN:2156-6976/ajcr0018905
Original Article
Evaluation of 9-cis retinoic acid and mitotane as  
antitumoral agents in an adrenocortical  
xenograft model
Zoltán Nagy1, Kornélia Baghy2, Éva Hunyadi-Gulyás3, Tamás Micsik2, Gábor Nyírő4, Gergely Rácz2, Henriett 
Butz4, Pál Perge1, Ilona Kovalszky2, Katalin F Medzihradszky3, Károly Rácz1,4, Attila Patócs4,5, Peter Igaz1
1The 2nd Department of Medicine, Faculty of Medicine, Semmelweis University, H-1088 Budapest, Szentkirályi 
Str. 46., Hungary; 2The 1st Department of Pathology and Experimental Cancer Research, Faculty of Medicine, 
Semmelweis University, H-1088 Budapest, Üllői Str. 26., Hungary; 3Laboratory of Proteomics, Biological Research 
Centre, H-6726 Szeged, Temesvári Krt. 62., Hungary; 4Molecular Medicine Research Group, Hungarian Academy 
of Sciences and Semmelweis University, Szentkirályi Str. 46., H-1088 Budapest, Hungary; 5“Lendület-2013” 
Research Group, Hungarian Academy of Sciences and Semmelweis University, Szentkirályi Str. 46., H-1088 
Budapest, Hungary
Received October 31, 2015; Accepted November 7, 2015; Epub November 15, 2015; Published December 1, 
2015
Abstract: The available drug treatment options for adrenocortical carcinoma (ACC) are limited. In our previous stud-
ies, the in vitro activity of 9-cis retinoic acid (9-cisRA) on adrenocortical NCI-H295R cells was shown along with its 
antitumoral effects in a small pilot xenograft study. Our aim was to dissect the antitumoral effects of 9-cisRA on ACC 
in a large-scale xenograft study involving mitotane, 9-cisRA and their combination. 43 male SCID mice inoculated 
with NCI-H295R cells were treated in four groups (i. control, ii. 9-cisRA, iii. mitotane, iv. 9-cisRA + mitotane) for 28 
days. Tumor size follow-up, histological and immunohistochemical (Ki-67) analysis, tissue gene expression micro-
array, quantitative real-time-PCR for the validation of microarray results and to detect circulating microRNAs were 
performed. Protein expression was studied by proteomics and Western-blot validation. Only mitotane alone and the 
combination of 9-cisRA and mitotane resulted in significant tumor size reduction. The Ki-67 index was significantly 
reduced in both 9-cisRA and 9-cisRA+mitotane groups. Only modest changes at the mRNA level were found: the 
9-cisRA-induced overexpression of apolipoprotein A4 and down-regulation of phosphodiesterase 4A was validated. 
The expression of circulating hsa-miR-483-5p was significantly reduced in the combined treatment group. The SET 
protein was validated as being significantly down-regulated in the combined mitotane+9-cisRA group. 9-cisRA might 
be a helpful additive agent in the treatment of ACC in combination with mitotane. Circulating hsa-miR-483-5p could 
be utilized for monitoring the treatment efficacy in ACC patients, and the treatment-induced reduction in protein SET 
expression might raise its relevance in ACC biology.
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Introduction
Adrenocortical carcinoma (ACC) is a rare tumor 
(incidence is 0.5-2 cases/million people/year) 
with poor prognosis in its advanced stages [1]. 
The primary treatment is surgical resection. 
Even with the most widely used EDPM (etopo-
side, doxorubicin, cisplatin, mitotane) chemo-
therapeutic regimen, the median overall sur-
vival was only 14.8 months in the recent FIRM-
ACT trial [2, 3]. Mitotane (o,p-DDD) is the only 
adrenal specific drug that is registered for the 
treatment of ACC [4]. Despite its numerous side 
effects and largely unknown mechanism of 
action this agent is used in the clinical practice 
for more than 50 years [5]. Intensive efforts are 
therefore going on for finding novel, effective 
drugs with fewer side effects.
In our previous in silico study of adrenocortical 
tumors genomics data, we have found that reti-
noic acid signaling via retinoid X receptor is 
an important pathogenic pathway in ACC [6]. 
Based on these in silico data, we have per-
formed in vitro studies on the NCI-H295R ACC 
cell line and found that 9-cis retinoic acid 
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(9-cisRA) was able to diminish hormone syn- 
thesis and cell viability in a concentration- and 
time-dependent manner, and it induced signifi-
cant gene expression changes [7]. In a pilot 
in vivo xenograft study in nude mice, 9-cisRA 
reduced tumor growth, as well [7].
In the present study, we aimed to further dis-
sect the antitumoral effect of 9-cisRA on ACC 
in a large xenograft study involving both mito-
tane and 9-cisRA and their combination. We 
have applied multimodal molecular biological, 
genomic and proteomic approaches to deci-
pher the molecular way of action of the agents 
tested.
Materials and methods
Cell culture
The human adrenocortical NCI-H295R cell line 
was obtained from the American Type Culture 
Collection (Manassas, VA, USA). Cells were cul-
tured in Dulbecco’s modified Eagle’s medium/
Nutrient Mixture F-12 Ham (DMEM: F12) sup-
plemented with 3.61*10-8 M selenium (Sigma-
Aldrich, St. Louis, MO, USA), 1.92*10-5 M lin-
oleic acid, 0.001 M insulin, 7.81*10-8 M trans-
ferrin (Sigma-Aldrich), 1.899*10-5 M bovine 
serum albumin and adjusted to a final concen-
tration of 1% HEPES, 1% Penicillin/Streptomy- 
cin (Sigma-Aldrich), 2.5% Nu-Serum (BD Bio- 
sciences, San Jose, CA, USA) and 2.5% L-gluta- 
mine (Sigma-Aldrich) at 37°C in a humidified 
5% CO2 atmosphere. The medium was changed 
two or three times a week and subcultured 
once or twice a week.
Xenograft model
44 male BALB/c SCID (severe combined immu-
nodeficiency) mice aged 6-8 weeks with aver-
age weight between 21-23 g were injected sub-
cutaneously with NCI-H295R cell suspension 
(107 cells/200 µl PBS). Treatment was started 
when the solid tumor reached 3 mm mean 
diameter (37 days after the H295R inocula-
tion). The animals have received the treatment 
by oral gavage for 28 days. Four groups were 
established: 1. control: 200 µl corn oil/day; 2. 
mitotane: 200 mg/kg/day/200 µl corn oil; 3. 
9-cis retinoic acid: 5 mg/kg/day/200 µl corn 
oil; and 4. mitotane 200 mg/kg/day/100 µl 
corn oil + 9-cis retinoic acid 5 mg/kg/day/100 
µl corn oil. The tumors were measured twice a 
week with a caliper by the same investigator. 
The volumes of the tumors were calculated by 
the following formula: (a*a*b*π)/6 [8]. On day 
29 after starting the treatments, the animals 
were killed by cervical dislocation in ether anes-
thesia. Only one animal died before day 29 due 
to technical problems.
Tumors were removed and their weights were 
measured. One half of the tumor was fixed 
in formalin for histological and immunohisto-
chemical examination, the other half was fro-
zen in liquid nitrogen and stored at -80°C until 
use. Lungs, heart, kidneys, spleen and liver 
were also removed for histological analysis. 
Whole blood was collected, then plasma was 
isolated and stored at -80°C until use. All ani-
mal experiments were conducted according 
to the ethical standards of the animal Health 
Care and Control Institute, Csongrád County, 
Hungary, permit No. XVI/02037-2/2008.
Histological and immunohistochemical analy-
sis
Four µm sections of formalin-fixed paraffin-
embedded tissues were dewaxed with xylene 
and ethanol and processed either for hematox-
ylin-eosin (HE) staining or Ki-67 immunostain-
ing. Ki-67 immunostaining (antibody: Cat. No. 
M7240, DakoCytomation, Glostrup, Denmark; 
dilution 1:400) was conducted using a Leica 
BOND-MAX automated immunostaining system 
(Leica Biosystems, Wetzlar, Germany). Slides 
were scanned by Pannoramic Flash II scan- 
ner, and digital slides were analyzed by Pannor- 
amic viewer software (3DHistech, Budapest, 
Hungary). Different regions of the viable xeno-
graft tumor were annotated and Ki-67 positive 
and negative cells were individually marked on 
these regions of interests (ROIs). Proliferation 
index was given in percentages of positive 
cells. 4-8 slides of each group with good quality 
were selected for analysis, and 3-5 ROIs/slides 
were counted with 4498-6273 cells in average. 
Ki-67 expression was scored by three indepen-
dent pathologists in a blinded fashion.
RNA isolation from tumor tissue
Total RNA was isolated from the frozen tumors 
with Qiagen miRNeasy Mini Kit according to the 
manufacturer’s protocol (Qiagen, Hilden, Ger- 
many). RNA concentration was measured with 
NanoDrop 2000 spectrophotometer. (Thermo 
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Fisher Scientific, Waltham, Mam USA). RNA 
integrity was determined by Agilent 2100 Bio- 
analyzer System (Agilent Technologies, Santa 
Clara, CA, USA). Samples with an RNA integrity 
number (RIN) above 8.0 were used for further 
analysis. RNA was stored at -80°C until use.
Messenger RNA (mRNA) expression profiling
Gene expression profiling was performed on 16 
samples (4-4 samples from each group) using 
a single-color array method by 4x44K Agilent 
Whole Genome Microarray slides (Agilent Tech- 
nologies).
Total RNA (200 ng) was labeled and amplified 
using the low Input Quick Amp Labeling Kit 
according to the instructions of the manufac-
turer. Labeled RNA was purified and hybridized 
to Agilent Human Gene Expression Microarray 
4x44K array slides, according to the manufac-
turer’s protocol. After washing, array scanning 
and feature extraction was performed with 
default scenario by Agilent DNA Microarray 
Scanner. Fluorescence intensities of spots 
were quantified, background subtracted, and 
dye normalized by Feature Extraction software, 
version 11.0.1 (Agilent Technologies). The raw 
data were analyzed with GeneSpring 12.6 soft-
ware (Agilent Technologies).
Reverse transcription quantitative polymerase 
chain reaction (RT-qPCR)
Seven genes were selected for validation by 
real-time RT-qPCR with Taqman gene expres-
sion assays (Thermo Fisher Scientific): MYC 
(Hs00153408_m1), APOA4 (Hs00166636_
m1), CXCR3 (Hs01847760_s1), BAALC (Hs00- 
227249_m1), PDE4A (Hs00183479_m1), PR- 
DM1 (Hs00153357_m1) and TGFBI (Hs009- 
32747_m1). Based on the selection criteria of 
Cheng et al. [9] and our previous study [10], 
ZNF625 (Hs00377010_m1) was chosen as ref-
erence gene.
Total RNA (10 ng) was reverse transcribed using 
High-Capacity RNA-to-cDNA Kit (Thermo Fisher 
Scientific). Quantitative RT-PCR was perform- 
ed by TaqMan Fast Universal PCR Master Mix 
(2×) (Thermo Fisher Scientific) on a 7500 Fast 
Real-Time PCR System (Thermo Fisher Scienti- 
fic) according to the manufacturer’s protocol. 
Samples were run in triplicate. For the evalua-
tion of the data we used the ddCT method [11] 
using Microsoft Excel 2010 (Microsoft Corpo- 
ration).
RNA isolation from plasma
Total RNA was isolated from 100 µl plasma 
samples with Qiagen miRNeasy Serum/Plasma 
Kit according to the attached manufacturer’s 
protocol (Qiagen) amended with addition of a 
spike-in control miRNA cel-miR-39 (2594091) 
(Qiagen). RNA concentration was measured 
with NanoDrop 2000 spectrophotometer (Ther- 
mo Fisher Scientific). RNA was stored at -80°C 
until use.
RT-qPCR for circulating microRNA measure-
ment
Based on our previous studies and literature 
data, four microRNAs were selected for valida-
tion by RT-qPCR with Taqman miRNA assays 
(Thermo Fisher Scientific): hsa-miR-181b (00- 
1098), hsa-miR-184 (000485), hsa-miR-210 
(000512) and hsa-miR-483-5p (002338). Cel-
mir-39 (000200) was used as reference gene 
[12].
Total RNA (1 µl) was reverse transcribed using 
specific TaqMan miRNA assays and TaqMan 
MicroRNA Reverse Transcription Kit (Thermo 
Fisher Scientific) on Proflex Base PCR System 
(Thermo Fisher Scientific). Quantitative RT-PCR 
was performed by TaqMan Fast Universal PCR 
Master Mix (2×) and TaqMan miRNA assays on 
a 7500 Fast Real-Time PCR System. PCR reac-
tions were run in triplicate. Negative control 
reactions did not include cDNA templates.
RT-qPCR for tissue microRNA measurement
Considering the results from the circulating 
microRNA measurements, tissue hsa-miR-
483-5p (002338) was studied by RT-qPCR with 
Taqman miRNA assays according to the instruc-
tions of the manufacturer. Four reference genes 
were used: U6 (001973), RNU6B (001093), 
RNU44 (001094) and RNU48 (001006).
Proteomics study
Equal amount of protein lysates (20-20 µg of 
each sample, 3 samples from each group) were 
separated by SDS-PAGE on a 10% minigel and 
stained with colloidal Coomassie Brillant Blue. 
The gel lanes were cut to 10 pieces and their 
protein content were in-gel digested with tryp-
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sin (Promega, Fitchburg, WI, USA) for 4 hours at 
37°C after reduction with dithiotreitol and alkyl-
ation with iodoacetamide. The digestion reac-
tion was stopped by acidification with formic 
acid, and the tryptic peptides were extracted 
from the gel and dried.
Samples were redissolved in 30 µl of 0.1% 
formic acid and subjected to LC-MSMS (Li- 
quid Chromatography-Mass Spectrometry and 
Liquid Chromatography-Tandem Mass Spec- 
trometry b, on a Waters nanoAcquity ULC on-
line coupled to an Orbitrap Elite Mass spec-
trometer) analysis. 5 µl sample was loaded 
onto a Symmetry C18 (5 µm, 180 µm ×20 mm) 
trap column (Waters, 186003514) in 3% of sol-
vent B and analyzed on a BEH300 C18 (1.7 µm, 
075 µm ×250 mm) nanoAcquity UPLC column 
(Waters 186003815) using a gradient elution 
(3-40% of solvent B during 37 min, solvent A: 
0.1% formic acid in water, solvent B: was 0.1% 
formic acid in acetonitrile:DMSO (95:5)). The 
flow rate was 300 nl/min. The LTQ-Orbitrap 
Elite mass spectrometer operated in data 
dependent mode, each survey scan (full MS 
measured in the Orbitrap R=60000, m/z range: 
380-1600) was followed with ion-trap collision 
induced dissociation (CID) scans of the 10 
most intense peaks. Dynamic exclusion was 
used for 30 seconds and single charged ions 
were not selected for fragmentation.
Mass spectrometry raw data were converted to 
MSMS peak list files using PAVA script [13]. 
Peak list files corresponding to the same sam-
ple (10 to each) were merged and searched 
against the human, mouse species specified 
UniProtKB random concat (06.11.2014) pro-
tein database, containing 136244 human and 
74540 mouse proteins and their randomized 
sequences. The search was done with the fol-
lowing parameters: fully specific tryptic pep-
tides with maximum 2 missed cleavages were 
allowed. All cysteines were considered as carb-
amidomethylated and some variable modifica-
tion has been allowed: oxidized methionine, 
acetylation of protein N-termini and pyroglu-
tamic acid modification at peptide N-terminal 
glutamine. Parent mass tolerance was set to 
10 ppm, while fragment mass tolerance was 
0.6 Da. All database search were completed 
on our in-house ProteinProspector (ver. 5.14.1) 
(Baker, P.R. and Clauser, K.R. http://prospector.
ucsf.edu accessed: July 22. 2015) search en- 
gine.
Spectral count was used for semi-quantitation. 
The number of spectra identified a protein were 
normalized by the number of all identified spec-
tra in the sample. These relative spectral 
counts were compared in between the different 
samples.
Western-blot analysis
Based on our proteomic results and literature 
data, the SET (SET nuclear proto-oncogene) 
protein was chosen for Western-blot analysis 
on 3 samples from each group of the xenograft 
study and on altogether 6 human adrenocorti-
cal samples (2 normal adrenal cortices, 2 ACAs 
(adrenocortical adenoma) and 2 ACCs (adreno-
cortical cancer)). Normal human adrenal corti-
ces were obtained from patients operated for 
hypernephroma [14]. The study on human sam-
ples was approved by the Ethical Committee 
of the Hungarian Health Council and inform- 
ed consent was obtained from all patients 
involved.
Tumor tissues were pulverized in liquid nitrogen 
and lysed in 1 ml of Lysis Buffer (0.02 M Tris, 
0.15 M NaCl, 0.002 M EDTA, 0.5% Triton X- 
100, 0.5% Protease Inhibitor Cocktail (Sigma 
Aldrich), 0.01 M NaF, 0.002 M Na3VO4 on ice for 
30 minutes. Next, samples were centrifuged at 
13000 rpm for 15 min. Supernatants were kept 
and protein concentrations were measured as 
described before by Bradford [15]. 20 µg of 
total protein per sample was mixed with loading 
buffer containing β-mercaptoethanol and was 
incubated at 99°C for 5 min. Denatured sam-
ples were loaded onto a 10% polyacrylamide 
gel and were run for 30 min at 200 V on a Mi- 
ni Protean vertical electrophoresis equipment 
(Bio-Rad, Hercules, CA). Proteins were trans-
ferred onto a PVDF membrane (Milipore, Biller- 
ca, MA) by blotting overnight at 75 mA. Ponceau-
staining was applied to see the loading and 
blotting efficiency. Membranes were blocked 
with 5 w/v% non-fat dry milk (Bio-Rad) in TBS 
(0.15 M NaCl, 0.02 M Tris-HCl pH=7.5) for 1 
hour followed by incubation with either anti- 
SET antibody (ab1183, Abcam, Cambridge, MA, 
dilution 1:1000) or anti-β-actin antibody (A22- 
28, Sigma Aldrich) for 16 h at 4°C. Membranes 
were washed 5 times with TBST (TBS+0.05% 
Tween-20) then incubated with secondary, 
HRP-conjugated anti-rabbit (P0448, DakoCyto- 
mation) or anti-mouse (P0447, DakoCytoma- 
tion) antibodies for 1 hour. SuperSignal West 
Pico Chemiluminescent Substrate Kit (Pierce/
9-cis retinoic acid and mitotane in adrenal cancer
3649 Am J Cancer Res 2015;5(12):3645-3658
Thermo Fisher Scientific) and Kodak Image 
Station 4000 MM Digital Imaging System were 
used to visualize the signals. β-actin served as 
loading control. Band density was measured by 
ImageJ software (National Institutes of Health, 
Bethesda, MD, USA).
Statistical analysis
For the statistical analysis of tumor grow- 
th, Mann-Whitney U test was applied (SPSS 
Statistics 20, IBM). The analysis of Ki-67 index 
was performed by One-way ANOVA followed by 
Tukey’s post Hoc test or Kruskal-Wallis ANOVA 
& Median Test (STATISTICA 7.0) depending on 
the results of the Shapiro-Wilks normality test. 
P<0.05 was considered to be significant.
The results from the microarray data were ana-
lyzed by Genespring 12.6 software (Agilent 
Technologies). A filter on expression at the 20th 
percentile of raw signal values, then a 2-fold 
change filter was used, and One-way ANOVA 
was performed, followed by Tukey’s post Hoc 
test without Benjamini-Hochberg false discov-
ery rate calculation. RT-qPCR and proteomics 
data were analyzed by One-way ANOVA followed 
by Tukey’s post Hoc test (STATISTICA 7.0).
Western-blot was evaluated by Kruskal-Wallis 
ANOVA & Median Test (STATISTICA 7.0).
Results
Analysis of xenograft tumor growth
The normalized tumor volume (relative to the 
first measured volume) was smaller in all treat-
ed groups than in controls during the whole 
experiment. At the end of our experiment, the 
Figure 1. A. Normalized tumor volumes; B. Normalized tumor volumes at the end of the treatments on day 28; C. 
Representative images of the Ki-67 immunhistochemical analysis from the four treatment groups; D. Numerical 
values of the Ki-67 immunhistochemical analysis. (Average results by three independent investigators).
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average values of normalized tumor volumes 
were 22.48-fold, 9.3-fold, 12.3-fold and 8.22-
fold higher in the control, mitotane treated, 
9-cisRA-treated, and 9-cisRA+mitotane groups 
relative to the starting tumor volume, respec-
tively. The reduction in tumor size has been sig-
nificant in the mitotane only and 9-cisRA+ 
mitotane groups (Figure 1A and 1B).
Histology, Ki-67 scoring
Tumors in the 9-cis RA receiving groups 
appeared to be more differentiated compared 
to the control and mitotane groups by hema-
toxylin and eosin (H&E) staining. The Ki-67 pro-
liferation index scored blindly by three indepen-
dent pathologists was significantly lower in the 
9-cisRA (32.64 ± 3.07%) group in comparison 
to the control (54.23 ± 3.71%) and mitotane 
groups (46.35% ± 2.2%) (P=0.00018 vs. con-
trol; P=0.00022 vs. mitotane). The lowest Ki-67 
index was noted in the combined 9-cisRA+ 
mitotane group (25.6 ± 4.09%) that was signifi-
cantly smaller compared to all other groups 
(P=0.00018 vs. control; P=0.00018 vs. mito-
tane; P=0.01684 vs. 9-cisRA) (Figure 1C and 
1D). Among the other tissues, only moderate 
fatty lesions were observed in the liver, proba-
bly due to the corn oil vehicle. No signs of treat-
ment toxicity have been found. 
Microarray analysis
4 samples from each group (altogether 16 sam-
ples) have been subjected to microarray. By 
analyzing the raw data, we have found 483 
significant gene expression changes after the 
statistical analysis, but only by omitting the 
Benjamini-Hochberg false discovery rate (FDR). 
By using FDR, only two significantly differential-
ly expressed transcripts emerged whose bio-
logical relevance is unknown. Microarray data 
are accessible at Gene Expression Omnibus 
(GEO; www.ncbi.nlm.nih.gov/geo, accession nu- 
mber: GSE73417).
RT-qPCR validation
Seven genes have been selected for validation 
based on the microarray data chosen from 
genes with the highest positive and negative 
fold changes, taking into account literature 
data, as well. However, only two genes could be 
validated to be significantly differentially ex- 
pressed (Figure 2). The well-known 9-cis reti-
noic acid target gene APOA4 (apolipoprotein 
A4) turned out to be significantly overexpress- 
ed in the combined treated group relative to 
the control group (P=0.0045), whereas PDE4A 
(phosphodiesterase 4A) appeared to be signifi-
cantly underexpressed in the combined treat-
ment group (P=0.0024).
Proteomics analysis and Western-blot
47 significant protein changes have been found 
between the groups (Table 1). By considering 
literature data regarding the tumor biological 
relevance of these proteins, the SET protein 
[16-20] was chosen for validation by Western- 
blotting.
SET protein expression was smaller in all treat-
ed groups relative to control, but only reached 
the level of significance in the combined treat-
ed group (Figure 3A and 3C). To look at the 
Figure 2. Results of RT-qPCR validation of APOA4 and PDEA4 (n=6).
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Table 1. Treatment-induced significant protein changes (47 proteins) based on the results of pro-
teomic analysis (P<0.05)
UniProt ID Gene Name Protein Name
P30050 RPL12 60S ribosomal protein L12
Q13765 NACA Nascent polypeptide-associated complex subunit alpha
B1AK87 CAPZB Capping protein (Actin filament) muscle Z-line, beta
Q01105 SET Phosphatase 2A inhibitor I2PP2A
Q86SZ7 PSME2 PSME2 protein
P14314 PRKCSH Protein kinase C substrate 60.1 kDa protein heavy chain
Q5U8W9 HRMT1L2 Protein arginine methyltransferase 1 isoform 4
Q6DC98 LMNB1 LMNB1 protein
M0QZL1 BLVRB Flavin reductase (NADPH)
P61158 ACTR3 Actin-related protein 3
Q9UBQ7 GRHPR Glyoxylate reductase/hydroxypyruvate reductase
O75347 TBCA Tubulin-specific chaperone A
Q6NVY0 CACYBP Calcyclin binding protein
K7ES63 TUBB6 Tubulin beta-6 chain
P42126 ECI1 Enoyl-CoA delta isomerase 1
Q5T1M5 FKBP15 FK506-binding protein 15
O75477 ERLIN1 Erlin-1
H7BZ09 ANP32A Acidic leucine-rich nuclear phosphoprotein 32 family member A
E9PK45 FTH1 Ferritin heavy chain
P62714 PPP2CB Serine/threonine-protein phosphatase 2A catalytic subunit beta
P31040 SDHA Succinate dehydrogenase
H7C333 GBAS Protein NipSnap homolog 2
Q15404 RSU1 Ras suppressor protein 1
Q92882 OSTF1 Osteoclast-stimulating factor 1
D6RC06 HINT1 Histidine triad nucleotide-binding protein 1
P62888 RPL30 60S ribosomal protein L30
Q969G3 SMARCE1 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1
P61326 MAGOH Protein mago nashi homolog
Q16539 MAPK14 Mitogen-activated protein kinase 14
P10599 TXN Thioredoxin
Q9Y333 LSM2 U6 snRNA-associated Sm-like protein LSm2
P26885 FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2
Q9UJV8 PURG Purine-rich element-binding protein gamma
P04080 CSTB Cystatin-B
E5RJH5 ENO3 Beta-enolase
P28062 PSMB8 Proteasome subunit beta type-8
P67775 PPP2CA Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform
Q53G26 DNAJA3 DnaJ (Hsp40) homolog, subfamily A, member 3 variant
Q9UBI6 GNG12 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12
Q8NHP8 PLBD2 Putative phospholipase B-like 2
D6R9R5 SAR1B GTP-binding protein SAR1b
Q00169 PITPNA Phosphatidylinositol transfer protein alpha isoform
P63173 RPL38 60S ribosomal protein L38
Q5T6V5 C9orf64 UPF0553 protein C9orf64
A4D2P2 RAC1 Ras-related C3 botulinum toxin substrate 1 
potential relevance of SET in human adrenocor-
tical tumors, we have analyzed some human 
tissues in a preliminary study, and found that 
SET protein is undetectable in normal and ACA 
tissues, whereas it is expressed in ACC (Figure 
3B).
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microRNA expression
From the four selected circulating miRNAs, hsa-
miR-483-5p has been significantly underex-
pressed in the combined group relative to 
control (P=0.028) (Figure 4). The expression of 
the other three tested circulating microRNAs 
was unchanged. However, we have not found 
significant changes in the expression of tis- 
sue hsa-miR-483-5p. From the four reference 
genes tested for tissue microRNAs, RNU44 and 
RNU6B turned out to be the best for normaliz-
ing the results.
Discussion
Mitotane is the only available adrenal cortex 
specific agent in the therapy of adrenocortical 
cancer. Despite being used for more than 50 
years, its precise mechanism of action is large-
ly unknown [5]. The degeneration of mitochon-
dria, free radicals, inhibition of steroid biosyn-
thetic enzymes, lipid-mediated endoplasmic 
reticulum stress have all been suggested to 
take part in the action of mitotane [5, 21]. The 
narrow therapeutic range and frequent side 
effects of mitotane constitute serious prob-
lems in clinical practice. Based on our previous 
in vitro and pilot xenograft study [7], 9-cisRA 
appeared to be a promising agent in ACC treat-
ment. To further dissect its actions and to com-
pare it to mitotane, we have performed a large-
scale xenograft study involving 9-cisRA, mito-
tane and their combination. We have observed 
that these agents act together in a synergistic 
manner on tumor growth.
Contrary to the several human in vivo studies 
applying mitotane, there are only few studies 
on mitotane-treated xenograft models to date 
[22-27]. Since there was no uniformly defined 
dose of mitotane given to mice, we have cho-
sen the average amount used in published 
studies. The results of these studies on the 
effectiveness of mitotane in animal models are 
also contradictory. Lindhe et al. described that 
mitotane has antitumoral effect given simulta-
neously with the tumor cells inoculation [24], 
whereas Doghman et al. did not find any long-
lasting effect in a similar study [25]. Here, we 
have observed the antitumoral activity of mito- 
tane.
Figure 3. Results of Western-
blot analysis of SET expres-
sion. A: Representative image 
SET expression in the xeno-
graft model: I: Mitotane, II: 
Control, III: 9-cisRA, IV: Com-
bined treatment group; B: 
Representative image of SET 
expression from a normal hu-
man adrenocortical cortex (a) 
and ACC tissue (b); C: Results 
of the densitometry analysis 
of SET expression in the xeno-
graft model (n=3).
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Retinoids, the natural and synthetic derivates 
of vitamin A play crucial roles in cell differentia-
tion, growth, and death. The anti-proliferative 
and antitumoral effects [28] of 9-cisRA acting 
via the retinoid X receptor are well documented 
in many different types of tumors in vitro and in 
vivo e.g. gastric cell line [29], head and neck 
squamous cell line [30], neuroblastoma [31] 
and breast cancer [32].
The dose of 9-cis retinoic acid (5 mg/kg) was 
much less than the documented toxic dose 
[30] and it was comparable to other in vivo 
doses used in the literature [31, 33-35].
We have observed antitumoral effects of both 
9-cisRA and mitotane when used alone, but sig-
nificant reduction in tumor volume could only 
be achieved by groups receiving mitotane alone 
and the combination of mitotane and 9-cisRA. 
The Ki-67 index was the lowest in the group 
receiving the combined treatment. Despite 
mitotane was more effective than 9-cisRA as a 
single agent for reducing tumor size, the Ki-67 
index was lower in the 9-cisRA-treated group 
than in the mitotane only group (Figure 1). The 
background for this phenomenon is unclear.
To decipher the molecular mechanisms behind 
the observed effects on tumor growth and pro-
liferation, we have performed molecular analy-
sis at mRNA and protein levels. In our previous 
in vitro studies on the adrenocortical cell line 
NCI-H295R, we have observed that 9-cisRA 
affected the expression of more than 2000 
APOA4, a member of apolipoprotein family is a 
known 9-cisRA target gene that has important 
roles in fat and glucose metabolism [36], in 
antioxidant [37], and anti-atherogenic process-
es [38], but it has been suggested also as a 
predictive factor in inflammatory bowel disease 
[39, 40], and as a novel serum biomarker in 
ovarian, cervical cancer, and acute lymphocytic 
leukemia [41-44]. There are no data, however, 
on the potential relevance of APOA4 in adreno-
cortical tumors.
PDE4A, as a member of PDE (phosphodiester-
ase) family, act as crucial cAMP level regulator 
[45], and it is involved in the basic cell path-
ways and also takes part in cancer progression. 
Its inhibition has been associated with many 
antitumoral actions e.g. regression of brain 
tumors [46], reduced proliferation and angio-
genesis in lung cancer [47], reduced motility 
and invasion in colon [48] and breast cancer 
cell line [49], decreased growth of malignant 
melanoma [50]. In line with these observa-
tions, we have also observed reduced expres-
sion of PDE4A in the combined treatment 
group, thus PDE4A might also be involved in 
ACC pathogenesis or progression.
We hypothesize that after the long treatment 
period of 28 days, mRNA expression does not 
really reflects the altered tumor behavior. We 
have therefore turned to the protein level, 
where we have found 47 significantly differen-
tially expressed proteins by proteomics analy-
sis. We have chosen the SET protein from the 
Figure 4. The expressional difference of circulating hsa-miR-483-5p (n=6).
genes [7] whereas the effect 
of mitotane on gene expres-
sion was more limited [10]. 
In contrast to these in vitro 
data and the observed 
changes in tumor size and 
Ki-67 levels, we could ob- 
serve only modest changes 
in gene expression in the 
present study. By omitt- 
ing the Benjamini-Hochberg 
False Discovery Rate, 483 
genes were found to be sig-
nificantly genes, and from 
the 7 selected genes only 2 
(APOA4, PDEA4) was vali-
dated to be significantly dif-
ferentially expressed.
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significantly differentially expressed proteins 
for validation by Western-blot. As expected, 
SET expression was down-regulated by the 
treatments, showing the lowest expression in 
the combined treatment group.
Protein SET is an inhibitor of tumor suppressor 
PP2A (protein phosphatase 2A) that has wide-
spread actions in the cellular functions imply-
ing cell cycle [18], apoptosis [51] and cell migra-
tion [19]. Due its target PP2A, it also influences 
ß-catenin [20], c-Myc [17] and Akt [16] path-
ways, and via inhibition of nm23-H1 (NME/
NM23 nucleoside diphosphate kinase 1) it also 
promotes metastatic potential [52], and thus it 
is associated with tumor progression. SET over-
expression is described in many tu- 
mors e.g. Wilm’s tumor [53], acute lymphoblas-
tic leukaemia [54], chronic lymphocytic leuke-
mia and non-Hodgkin lymphoma [55], lung 
[56], colon [57], pancreatic [58], prostate [59] 
and ovarian cancer [60], as well. To the best of 
our knowledge, our study is the first to raise the 
potential relevance of SET in ACC biology.
We have performed a preliminary evaluation of 
SET protein expression in human adrenocorti-
cal tumor samples, as well. SET was weakly 
expressed in ACC, but absent from benign ade-
nomas and normal adrenocortical samples. 
This finding that certainly awaits validation on a 
larger cohort appears to support our xenograft 
findings where SET expression was the highest 
in the untreated xenograft, and suppressed in 
the treated samples parallel to tumor shrink- 
age.
In addition to our mechanistic efforts aimed at 
deciphering the molecular way of action of 
9-cisRA and mitotane in our xenograft model, 
we have also studied some circulating microR-
NAs as potential markers for treatment efficacy 
monitoring based on our previous studies in 
humans. Circulating hsa-miR-483-5p appears 
to be the best circulating microRNA marker of 
adrenocortical malignancy [61-63]. From the 
four analyzed circulating microRNAs, only hsa-
miR-483-5p expression was modulated by the 
treatments, and its expression was significantly 
suppressed by the combined 9-cisRA + mito-
tane treatment. Circulating hsa-miR-483-5p 
thus appears to be a marker of treatment effi-
cacy, and this could be relevant in the clinical 
setting, as well. Regarding the tissue expres-
sion of hsa-miR-483-5p, however, no signifi-
cant differences have been observed. We can 
conclude that the circulating and tissue hsa-
miR-483-5p alter independently. There are 
data that microRNAs can be changed parallel, 
contrary, or independently between the circula-
tion and tissues [64, 65], but the molecular 
mechanisms underlying these discrepancies 
and the regulation of adrenocortical hsa-miR-
483-5p expression are largely unknown, yet.
In conclusion, 9-cisRA might represent an alter-
native additive treatment option in ACC that 
seems to be most efficient when combined 
with mitotane. The tumor size, Ki-67, SET pro-
tein, and circulating hsa-miR-483-5p were all 
lowest in the group receiving the combined 
treatment that suggest synergistic action of 
9-cisRA and mitotane in our xenograft model. 
The molecular background of the observed syn-
ergistic mitotane-9-cisRA action is, however, 
unclear. We have found only modest gene 
expression changes, and although the number 
of affected proteins is higher, their list is not 
extensive, either. The decrease of SET protein 
expression by the treatments might be note-
worthy, as paralleled by its expression in human 
adrenocortical tumors. The potential applicabil-
ity of circulating hsa-miR-483-5p for monitor-
ing ACC treatment efficacy might be relevant in 
the clinical setting, as there is no reliable blood-
based tumor marker of ACC at present. Cir- 
culating microRNA might be exploited for treat-
ment monitoring in other diseases, as well.
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